The Japanese pharma is currently investigating mezagitamab’s potential in two late-stage autoimmune programmes.

Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that ...

Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational ...

BIDMC researchers have developed a new laboratory test to assist doctors in seeing whether blood-thinning medications are ...

Obesity threatens the health of men and women in different ways: the former are more likely to suffer from the accumulation of visceral fat and liver disorders, the latter from inflammation and high ...

For the first time, scientists have used a modern cell therapy called CAR-T to treat a patient with three different ...

Chris Connolly knows he would not be alive today without his organ donor and the dozens of blood donors who helped keep […] ...

Researchers have uncovered why a rare blood clotting disorder can occur after certain COVID-19 vaccines or adenovirus infections. The immune system can mistakenly target a normal blood protein (PF4) ...

Treatment reset wayward immune system of patient with life-threatening conditions, say scientists, in a world first ...

Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets. | Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.

In recent years, CAR T-cell therapy has become a revolutionary, if risky, treatment for some late-stage cancers. Yet CAR T ...